What 11 Analyst Ratings Have To Say About Mirati Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. The average price target for the stock is $63.09, with a high of $83.00 and a low of $48.00. The majority of the analysts are indifferent about the stock, with 2 being bullish, 2 somewhat bullish, and 7 indifferent. The average price target has increased by 4.91% over the past month.
November 07, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have a mixed opinion on Mirati Therapeutics (NASDAQ:MRTX) stock, with the majority being indifferent. The average price target has increased by 4.91% over the past month.
The stock has received mixed reviews from analysts, with the majority being indifferent. This could lead to uncertainty in the market, potentially affecting the stock's price. However, the increase in the average price target over the past month indicates a positive trend.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100